OrthoPediatrics Corp. (NASDAQ:KIDS – Get Free Report) Director David Pelizzon sold 22,500 shares of the company’s stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $23.35, for a total value of $525,375.00. Following the sale, the director directly owned 6,504,133 shares in the company, valued at approximately $151,871,505.55. This represents a 0.34% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.
OrthoPediatrics Stock Performance
Shares of KIDS opened at $22.41 on Friday. The stock has a market capitalization of $585.13 million, a PE ratio of -13.34 and a beta of 0.99. The business’s fifty day moving average price is $21.78 and its 200 day moving average price is $18.87. The company has a debt-to-equity ratio of 0.28, a current ratio of 4.78 and a quick ratio of 2.17. OrthoPediatrics Corp. has a 12-month low of $14.42 and a 12-month high of $26.74.
OrthoPediatrics (NASDAQ:KIDS – Get Free Report) last released its earnings results on Tuesday, August 4th. The company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.04. OrthoPediatrics had a negative net margin of 15.72% and a negative return on equity of 8.10%. The firm had revenue of $70.51 million during the quarter, compared to analyst estimates of $68.21 million. Equities research analysts forecast that OrthoPediatrics Corp. will post -1.14 EPS for the current year.
Institutional Inflows and Outflows
Wall Street Analysts Forecast Growth
A number of equities analysts have issued reports on the stock. BTIG Research raised their target price on shares of OrthoPediatrics from $24.00 to $29.00 and gave the stock a “buy” rating in a report on Thursday, August 20th. TD Cowen reaffirmed a “buy” rating on shares of OrthoPediatrics in a report on Monday, June 15th. Truist Financial set a $22.00 price target on OrthoPediatrics in a report on Wednesday, August 5th. Needham & Company LLC boosted their price objective on OrthoPediatrics from $30.00 to $35.00 and gave the company a “buy” rating in a research report on Wednesday, August 5th. Finally, Piper Sandler restated an “overweight” rating and set a $25.00 price objective (up from $22.00) on shares of OrthoPediatrics in a research report on Wednesday, August 5th. Nine research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, OrthoPediatrics has a consensus rating of “Moderate Buy” and an average target price of $26.44.
Read Our Latest Stock Analysis on OrthoPediatrics
OrthoPediatrics Company Profile
OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.
The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.
Featured Stories
- Five stocks we like better than OrthoPediatrics
- MarketBeat Week in Review – 08/31 – 09/04
- Revolution Medicines Got Its Breakthrough—What Moves It Next?
- Retail Earnings Just Exposed a Bigger Divide in the U.S. Consumer Economy
- FB Financial’s Southern Expansion and Buybacks Drive Analyst Optimism
Receive News & Ratings for OrthoPediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OrthoPediatrics and related companies with MarketBeat.com's FREE daily email newsletter.
